Bloomage Biotech(SH:688363) Mei Ri Jing Ji Xin Wen·2025-09-24 08:01Core Points - The controlling shareholder of Hyaluronic Acid Giant, Huaxi Biological, has increased its shareholding from 59.17% to 60.01%, with an investment exceeding 200 million RMB in just over a month [1][2] - The company has faced continuous performance decline over the past two years, with revenue and net profit dropping significantly [4][6] - Chairman Zhao Yan has returned to the front line of business, implementing a series of reforms to revitalize the company [3][4] Shareholding Increase - Huaxi Xingyu Investment Co., the controlling shareholder, acquired 4.036842 million shares between August 27 and September 19, 2025, raising its total shareholding to approximately 287.54 million shares [1] - The total investment amount for the share increase is projected to be around 250 million RMB, with plans to invest between 200 million and 300 million RMB within six months [2] Business Performance - Huaxi Biological's revenue for 2022, 2023, and 2024 was 6.359 billion RMB, 6.076 billion RMB, and 5.371 billion RMB, respectively, with net profits of 971 million RMB, 593 million RMB, and 174 million RMB [4] - The company's stock price has seen a drastic decline, with a maximum drop of 86.45% from its peak of 312.99 RMB in late 2021 to a low of 42.40 RMB in April 2025 [4] Management Changes - Several vice presidents have left the company as part of a management restructuring aimed at streamlining operations [4][5] - The company is focusing on a talent team with actionable capabilities and a strategic emphasis on scientific research [3] Revenue Breakdown - In the first half of 2025, Huaxi Biological reported a revenue of 2.261 billion RMB, a year-on-year decrease of 19.57%, with a net profit of 221 million RMB, down 35.38% [6] - The skin science innovation transformation business, the largest segment, generated 912 million RMB, a decline of 33.97%, while the nutrition science innovation transformation business saw a growth of 32.40% [6]